CELU · Celularity Inc
$1.71
+0.11 (+6.88%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 29, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated the Company's current financial position, liquidity, capital resources, and projected cash flows and has determined that there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Sep 29, 2026
Market Cap
$43.81M
Shares
32.45M
Volume · Oct 5
279.53K
Avg daily vol (3M)
3.9M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.60
Open$1.37
Day$1.36–1.64
52W close$0.60–2.27
Avg vol 30d8.2M
Short int821K · 2.5% float · 2.1d
Short vol56%
DataJan 2020–Oct 2026
Filing10-Q · Sep 29
Up next
filed Sep 29, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$18.97M
Trailing 12 months
Net income (TTM)
−$71.09M
Trailing 12 months
Revenue growth YoY
-66.3%
Year over year
Operating margin
-321.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+28.8%
Year over year · more shares
Price change (1Y)
-21.6%
Trailing year
Short interest
2.5%
Latest settlement · 2.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+46%
above
Price vs 50-day avg
+43%
above
RSI (14)
63
neutral
MACD trend
Positive
52-week position
60%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
+25%
trailing
YTD return
+44%
this year
Relative strength
+13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.53% of float · ▼ -56.7% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
39 holders — mid 3-yr range
Squeeze score
39
low risk · 0–100
Fundamentals
Revenue growth
−51%
Y/Y
Gross margin
25%
expanding
EPS growth
−36%
Y/Y
Free cash flow
$-13.4M
Quant / Vol
risk profile
Volatility
166%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
9.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+46%
Bullish
Price vs 50-day avg
+43%
Bullish
RSI (14)
63
Neutral
MACD trend
Positive
Bullish
52-week position
60%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
Golden cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.53% of float · ▼ -56.7% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
39 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 60%
Range high $2
vs 200-day avg +46%
vs 50-day avg +43%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CELU
this stock
Celularity Inc
|
$43.81M | +44.1% | -51.0% | — | 2.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CELU | +15.9% | -12.6% | +25.0% | +18.5% | +44.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +16.2% | -12.1% | +12.8% | +17.6% | +31.3% |